A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia - Wikidata - awgldk - TriplyDB

A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

http://www.wikidata.org/entity/Q37210059

about

Nebulized heparin for patients under mechanical ventilation: an individual patient data meta-analysis New parenteral anticoagulants in development.Defining and predicting severe community-acquired pneumonia.A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection.Defining severe pneumonia.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Airway tissue factor-dependent coagulation activity in response to sulfur mustard analog 2-chloroethyl ethyl sulfide Update in community-acquired and nosocomial pneumonia 2009.Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations Septic shock: new pharmacotherapy options or better trial design?Anticoagulant modulation of inflammation in severe sepsis.Precision medicine for the treatment of severe pneumonia in intensive care.New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.Role of clinical evaluation committees in sepsis trials: from 'valid cohort' assessment to subgroup analysis.Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.

P2860

Q26753103-9EACFE27-3D57-44F2-984F-7D6017E3CB32 Q33392647-927E4F58-713A-4D55-B547-C92FA5FCE674 Q33872274-D40D2620-1CDD-4B46-B1B7-88E698A5CFE3 Q33927961-6D96C088-6EED-4949-8E31-B796E5A87EC4 Q35184605-EA9AC501-BF4F-4844-BA41-BDDB4FAF8BD2 Q35752611-85AA6552-84DA-4FAF-ACF8-09123B1F9BB8 Q35950219-3BF23CE3-365F-4439-8108-55B39DAF7B48 Q37728782-AF99F4FF-931C-4F77-8EF3-CFE93DA29EE0 Q38006576-A057DD50-5BCC-4A22-8FB3-AA253D5702E8 Q38085693-E7C39AD5-8E4F-47FC-908F-8F2678704161 Q38457021-987E8BF5-2088-42D4-9354-CE76E4A0FEC0 Q38704065-774DD2DF-7E58-4D90-A828-EA7408B98B2F Q39213540-E12899D1-B445-47F8-AC0A-EF5AD36B7CD5 Q39979975-36BF803F-14AA-4DB7-B769-A84329DFE81B Q43903326-60D16F90-1A76-468B-BF0C-B1C4A44BDB8F

P2860

A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

http://www.wikidata.org/entity/Q37210059

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A clinical evaluation committe ...... e community-acquired pneumonia

@en

A clinical evaluation committe ...... issue factor pathway inhibitor

@nl

type

label

A clinical evaluation committe ...... e community-acquired pneumonia

@en

A clinical evaluation committe ...... issue factor pathway inhibitor

@nl

prefLabel

A clinical evaluation committe ...... e community-acquired pneumonia

@en

A clinical evaluation committe ...... issue factor pathway inhibitor

@nl

P1433

Q37210059-B6C680B5-17CC-4352-BD20-089FA173CAB7

P1476

Q37210059-5446D756-7208-4C7B-BE78-3F9AD73AA434

P2093

Q37210059-0F2864DA-3D91-4035-BDC8-6036A3D1A5E6

Q37210059-43C82CD8-32E3-41E7-BD81-CE174932BA63

Q37210059-449DE074-928E-4009-9768-422E349FAA06

Q37210059-49A7D781-EDA6-4FC1-9EB2-7979BE02723D

Q37210059-A4AED562-4481-47F9-8A9F-68E67BB2A856

Q37210059-B94E921A-0A38-4AE6-B730-B6B80641071D

Q37210059-F6A8D600-276F-40BA-903A-B4F58941A732

P2860

Q37210059-07DAD518-7CA9-40B3-B5BE-F243CCEB95D2

Q37210059-1166EDC9-FD2B-4990-93B5-022A12152BA0

Q37210059-2E8759DB-357D-41D4-A960-F9BC32F49BE8

Q37210059-2EE846F0-E8FA-4987-BBFD-D3C88381EDB2

Q37210059-305CD825-9F61-4C93-833D-2CDF2A8D8C8F

Q37210059-306C734D-86E8-4526-A962-DD4A2A80E4F2

Q37210059-3284FC70-B3F7-41FD-8461-36402FBFDECC

Q37210059-3997D775-C72A-4516-B740-B1615B501828

Q37210059-3C54F673-E8B0-418B-B5C9-45439D911AEB

Q37210059-4D1DCE3E-23CC-43F7-84B6-81E76E189349

P2888

Q37210059-590EE458-D8C8-4F29-81AC-0F1C343DAE3F

P304

Q37210059-8F8F4DD9-6275-48CF-AC76-B2078A778B60

P31

Q37210059-F54F18AA-4947-4116-8B7E-8FAA1F93BB27

P356

Q37210059-07D2A8AF-2F56-4321-A84A-435E4A81D214

P433

Q37210059-8271D973-2E5F-4F21-AF08-160AF1E93C05

P478

Q37210059-3A2C4EE2-7875-4CAE-948E-1D106D367594

P50

Q37210059-3AC08634-F7C8-4903-B161-7C0A9CBD2F71

P577

Q37210059-BB9A33BD-9F42-465D-ACDC-18683BEE33AF

P5875

Q37210059-01346934-8EC0-47E2-994B-406CD2B43CBF

P6179

Q37210059-943E9A18-A973-4E96-B4B9-8771BBDA13A7

P698

Q37210059-E4E51394-B100-423E-AC86-E94374F52D05

P921

Q37210059-76FEE0B4-18E3-45F7-935D-5CB58DAFC566

P932

Q37210059-D8D79B71-E3BE-4DB1-B467-0A89F25AF263

P356

P1433

P1476

A clinical evaluation committe ...... e community-acquired pneumonia

@en

P2093

Abla A Creasey

http://www.w3.org/2001/XMLSchema#string

Edward Abraham

http://www.w3.org/2001/XMLSchema#string

Fang Xie

http://www.w3.org/2001/XMLSchema#string

Lona Poole

http://www.w3.org/2001/XMLSchema#string

Pierre-François Laterre

http://www.w3.org/2001/XMLSchema#string

Steven M Opal

http://www.w3.org/2001/XMLSchema#string

Steven P LaRosa

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

Structure and biology of tissue factor pathway inhibitor

Efficacy and safety of recombinant human activated protein C for severe sepsis

Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation.

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia.

Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.

P2888

P304

R36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC7747

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Richard G. Wunderink

P577

2009-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24199508

http://www.w3.org/2001/XMLSchema#string

P6179

1031628297

http://www.w3.org/2001/XMLSchema#string

P698

19284881

http://www.w3.org/2001/XMLSchema#string

P921

P932

2689471

http://www.w3.org/2001/XMLSchema#string